Belluscura Future Growth
Future criteria checks 2/6
Belluscura is forecast to grow earnings and revenue by 127.6% and 151.8% per annum respectively while EPS is expected to grow by 133.9% per annum.
Key information
127.6%
Earnings growth rate
133.9%
EPS growth rate
| Medical Equipment earnings growth | 14.2% |
| Revenue growth rate | 151.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 25 | 0 | N/A | 1 | 2 |
| 12/31/2024 | 5 | -10 | N/A | -7 | 1 |
| 6/30/2024 | 2 | -19 | -14 | -10 | N/A |
| 3/31/2024 | 1 | -19 | -14 | -9 | N/A |
| 12/31/2023 | 1 | -19 | -14 | -9 | N/A |
| 9/30/2023 | 1 | -14 | -15 | -10 | N/A |
| 6/30/2023 | 1 | -10 | -17 | -11 | N/A |
| 3/31/2023 | 1 | -9 | -18 | -13 | N/A |
| 12/31/2022 | 1 | -8 | -20 | -15 | N/A |
| 9/30/2022 | 1 | -8 | -18 | -14 | N/A |
| 6/30/2022 | 1 | -7 | -17 | -14 | N/A |
| 3/31/2022 | 1 | -6 | -13 | -10 | N/A |
| 12/31/2021 | 0 | -5 | -10 | -7 | N/A |
| 9/30/2021 | 0 | -5 | -7 | -5 | N/A |
| 6/30/2021 | N/A | -4 | -5 | -3 | N/A |
| 3/31/2021 | N/A | -3 | -4 | -2 | N/A |
| 12/31/2020 | N/A | -2 | -3 | -1 | N/A |
| 12/31/2019 | 0 | -2 | -2 | -1 | N/A |
| 12/31/2018 | 0 | -1 | -3 | -2 | N/A |
| 12/31/2017 | 0 | -3 | N/A | -2 | N/A |
| 11/30/2016 | 0 | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9VQ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9VQ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9VQ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9VQ's revenue (151.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 9VQ's revenue (151.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 9VQ's Return on Equity is forecast to be high in 3 years time